查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1474906

mRNA 药物市场规模、份额、趋势分析报告：按应用、类型、最终用途、地区、细分市场预测，2024-2030 年

mRNA Therapeutics Market Size, Share & Trends Analysis Report By Application (Rare Genetic Diseases, Oncology, Respiratory Diseases, Infectious Diseases), By Type (Prophylactic, Therapeutic), By End-use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

mRNA药物市场的成长与趋势：

Grand View Research的最新报告显示，到2030年，全球mRNA药物市场预计将达到313亿美元。

预计2024年至2030年复合年增长率为17.05%。推动市场成长的主要因素之一是糖尿病、爱滋病毒、癌症和心血管疾病等慢性病和感染疾病的盛行率不断上升。对抗伊波拉出血热、流感、爱滋病毒和最近的 COVID-19 等病毒性疾病的治疗和疫苗接种需求不断增长，预计将推动产业成长。 COVID-19病毒引起了许多政府机构和疫苗製造商的关注，这有望加速市场扩张。

此外，多家供应商正在使用新技术，例如将第一阶段和第二阶段临床试验阶段结合起来，并更快地获得卫生当局的监管批准，以预测在此期间全球疫苗接种剂量的可用性，预计将有助于疫苗接种量的成长行业。与传统药物相比，透过使用最尖端科技，可以生产出 mRNA 疫苗和治疗药物。这些产品的製造成本较低，抗感染疾病能力更强，并且具有增强的免疫抗原性。用于 mRNA 体内系统递送的脂质奈米颗粒成分的进步也为市场扩张创造了良好的前景。

例如，2022 年 3 月，美国国立卫生研究院下属国家过敏和感染疾病研究所 (NIAID) 报告称，我们已开始一项评估三种潜在 HIV 疫苗的 1 期临床试验。因此，需求将会增加，进一步支撑产业的成长。

作为另一个重要的成长动力，製药公司正在投资 mRNA 技术。预计该市场也将受到生物技术相关研发（R&D）措施和医疗技术进步等其他因素的推动。例如，Moderna 和阿斯特捷利康正在合作使用 mRNA 治疗心肌缺血（一种心臟疾病，当流向心臟的血流减少，导致心肌缺氧时发生）。同样，Arcturus Therapeutics 正在测试针对心臟病的 mRNA 疗法。此类投资可能会补充未来几年的市场成长。

COVID-19 大流行预计将对行业成长产生积极影响。 COVID-19 疫苗是一种使用 mRNA 技术治疗的疾病。 COVID-19疫苗主要用于癌症治疗，是推动mRNA市场的主要因素。由于冠状病毒突变和病毒变种传播的可能性，mRNA 公司正在努力开发下一代 COVID-19 疫苗。例如，2022 年 6 月，食品药物管理局核准Moderna COVID-19 疫苗和辉瑞 &BioNTech COVID-19 疫苗用于 6 个月大的儿童，作为预防 COVID-19 的措施。因此，在 COVID-19 大流行期间，这些技术的使用预计会增加，从而带动产业成长。

此外，近年来出现了明显的整合趋势，参与者结成策略联盟以支持当前的研发计划。例如，2021 年 2 月，葛兰素史克 (GlaxoSmithKline plc) 和 CureVac NV 宣布达成一项价值 1.5236 亿美元的新协议，以在当前合作伙伴关係的基础上开发下一代 COVID-19 mRNA 疫苗。随着领先的基于 mRNA 的疗法/疫苗通过临床试验展示概念验证、进展并最终推向市场，在可预见的未来，这一专业行业领域的利益相关人员的机会将继续增长，预计将显着增加。

mRNA 製药市场报告亮点

  • 按应用，市场进一步细分为罕见遗传疾病、肿瘤、呼吸系统疾病、感染疾病等。
  • 按类型划分，市场进一步细分为预防和治疗。至2023年，预防领域将完全主导市场，份额达100%。
  • 根据最终用途，市场进一步细分为医院/诊所、研究机构等。预计到2023年，医院和诊所领域将占据市场主导地位，份额为45.36%，并在2024年至2030年期间增长最快。
  • 北美mRNA药物收益占有率最大，2023年市占率为40.37%。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章 市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/辅助市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 产业分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19 影响分析

第 4 章应用程式的商业分析

  • 使用细分仪表板
  • mRNA医药市场：应用变化分析
  • 2018-2030 年 mRNA 药物市场规模与趋势分析（按应用）
  • 罕见遗传疾病
  • 瘤
  • 呼吸系统疾病
  • 感染疾病
  • 其他的

第五章业务分析的类型

  • 类型细分仪表板
  • mRNA药物市场：类型变异分析
  • 2018-2030 年 mRNA 药物市场规模及趋势分析（按类型）
  • 预防
  • 治疗

第 6 章最终用途业务分析

  • 最终用途细分仪表板
  • mRNA 药物市场：最终用途变异分析
  • 2018-2030 年 mRNA 药物市场规模与趋势分析（依最终用途）
  • 医院/诊所
  • 研究机构
  • 其他的

第七章 区域业务分析

  • 区域仪表板
  • 2023 年和 2030 年市场规模和预测/趋势分析
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 泰国
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 公司分类
  • 策略规划
  • 2023 年企业市场分析
  • 公司简介/上市公司
    • Moderna Inc.
    • BioNTech SE
    • CureVac NV
    • Arcturus Therapeutics
    • Sanofi
    • GSK plc.
    • Argos Therapeutics Inc.
    • Ethris
    • Pfizer Inc.
    • AstraZeneca
Product Code: GVR-4-68039-957-3

mRNA Therapeutics Market Growth & Trends:

The global mRNA therapeutics market size is expected to reach USD 31.30 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 17.05% from 2024 to 2030. One of the main factors propelling the market growth is the rising incidence of chronic and infectious diseases like diabetes, HIV, cancer, and CVDs. The growing need for therapeutic drugs and vaccinations to combat viral illnesses like Ebola, influenza, HIV, and most recently COVID-19 is expected to fuel industry growth. The COVID-19 virus has been the focus of numerous government organizations and vaccine producers, and it is anticipated that this will accelerate market expansion.

Furthermore, the availability of vaccination doses around the world is projected to increase during the forecast period as a result of multiple suppliers using novel techniques, such as combining the phase 1 and phase 2 clinical trial stages and obtaining regulatory clearances more quickly from health agencies, thus contributing to the industry growth. With the use of cutting-edge technologies, mRNA vaccines and therapeutics are generated in comparison to conventional medications. These products are less expensive to produce, more powerful against infections, and have enhanced immunogenicity. A favorable outlook for market expansion is also being created by advancements in the compositions of lipid nanoparticles for in-vivo systemic delivery of mRNA.

For instance, in March 2022, The National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) launched a phase 1 clinical trial to assess three potential HIV vaccines using a messenger RNA (mRNA) platform due to its active component and direct the cells to make a protein (or perhaps a protein fragment) that stimulates an immune response using artificial mRNA created in a lab, which enhances the vaccine with more specificity as well as robust stability. Thus, it will increase the demand and further boost the industry growth.

As another significant growth-inducing element, pharmaceutical firms are spending on mRNA technology since they can combine numerous molecules into a therapeutic drug. The market is expected to be driven by additional factors, such as significant biotechnology-related research and development (R&D) initiatives and advancements in medical technology. For instance, Moderna and AstraZeneca are working together on a myocardial ischemia therapy using mRNA (a form of cardiac disease that develops when there is a decrease in blood flow to the heart, depriving the heart muscle of necessary oxygen). Similarly, mRNA treatments for heart disease are also being tested by Arcturus Therapeutics. Such investments are likely to supplement the market growth in the coming years.

The COVID-19 pandemic is anticipated to positively impact the industry growth. The COVID-19 vaccine is one of the diseases for which the mRNA technology is being used. In addition to its predominant use in cancer therapy, the COVID-19 vaccine is the main factor driving the market for mRNA. The mRNA firms are working hard to create COVID-19 vaccines for the next generation due to the coronavirus mutation and the potential spread of virus variants. For instance, in June 2022, The Food and Drug Administration approved the Moderna COVID-19 Vaccine and also the Pfizer & BioNTech COVID-19 Vaccine for use in children as young as 6 months old as COVID-19 preventative measures. As a result, the usage of these technologies is projected to increase during the COVID-19 pandemic and result in industry growth.

Additionally, there has been a discernible trend toward consolidation over the past few years, with players forming strategic alliances to support current R&D projects. For instance, in February 2021, building on their current partnership, GlaxoSmithKline plc and CureVac N.V. announced a new USD152.36 million agreement to create COVID-19 next-generation mRNA vaccines with the possibility for a multi-valent strategy to address numerous developing variations in a single vaccination. As additional mRNA-based therapeutic / vaccine leads exhibit proof-of-concept, go through clinical testing, and eventually hit the market, the opportunity for stakeholders involved in this specialized industry segment is likely to experience a significant increase in the predicted future.

mRNA Therapeutics Market Report Highlights:

  • Based on applications, the market is further segmented into rare genetic diseases, oncology, respiratory diseases, infectious diseases, and others.
  • Based on types, the market is further categorized into prophylactic and therapeutic. The prophylactic segment completely dominated the market with a share of 100% in 2023.
  • Based on end-uses, the market is further segmented into hospitals & clinics, research organizations, and others. The hospitals & clinics segment dominated the market with a share of 45.36% in 2023 and is expected to register the fastest growth rate from 2024 to 2030
  • The North America mRNA therapeutics market accounted for the largest revenue share of 40.37% share in 2023

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Application Segment
    • 1.1.2. Type Segment
    • 1.1.3. End-use Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Primary Research
  • 1.6. Information or Data Analysis:
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Validation
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. List of Abbreviations
  • 1.11. Objective

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising prevalence of cancer
      • 3.2.1.2. Academic and industrial interest in mRNA
      • 3.2.1.3. Advantages of mRNA vaccines
      • 3.2.1.4. Growing demand for therapeutic medicines
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Stringent government regulations for mRNA-based product approvals
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Application Business Analysis

  • 4.1. Application Segment Dashboard
  • 4.2. mRNA Therapeutics Market Application Movement Analysis
  • 4.3. mRNA Therapeutics Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 4.4. Rare Genetic Diseases
    • 4.4.1. Rare genetic diseases market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.5. Oncology
    • 4.5.1. Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.6. Respiratory Diseases
    • 4.6.1. Respiratory diseases market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.7. Infectious Diseases
    • 4.7.1. Infectious diseases market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. Type Business Analysis

  • 5.1. Type Segment Dashboard
  • 5.2. mRNA Therapeutics Market Type Movement Analysis
  • 5.3. mRNA Therapeutics Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 5.4. Prophylactic
    • 5.4.1. Prophylactic market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5. Therapeutic
    • 5.5.1. Therapeutic market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. End-use Business Analysis

  • 6.1. End-use Segment Dashboard
  • 6.2. mRNA Therapeutics Market End-use Movement Analysis
  • 6.3. mRNA Therapeutics Market Size & Trend Analysis, by End-use, 2018 to 2030 (USD Million)
  • 6.4. Hospitals & Clinics
    • 6.4.1. Hospitals & clinics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5. Research Organizations
    • 6.5.1. Research organizations market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis by Application, Type, End-use

  • 7.1. Regional Dashboard
  • 7.2. Market Size & Forecast and Trend Analysis, 2023 & 2030
  • 7.3. North America
    • 7.3.1. North America mRNA Therapeutics Market, 2018 - 2030 (USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Scenario
      • 7.3.2.3. Market Scenario
      • 7.3.2.4. Regulatory Framework
      • 7.3.2.5. Disease Prevalence
      • 7.3.2.6. Reimbursement Scenario
      • 7.3.2.7. U.S. mRNA Therapeutics Market, 2018 - 2030 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Competitive Scenario
      • 7.3.3.3. Market Scenario
      • 7.3.3.4. Regulatory Framework
      • 7.3.3.5. Disease Prevalence
      • 7.3.3.6. Reimbursement Scenario
      • 7.3.3.7. Canada mRNA Therapeutics Market, 2018 - 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. Europe mRNA Therapeutics Market, 2018 - 2030 (USD Million)
    • 7.4.2. UK
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Market Scenario
      • 7.4.2.4. Regulatory Framework
      • 7.4.2.5. Disease Prevalence
      • 7.4.2.6. Reimbursement Scenario
      • 7.4.2.7. UK mRNA Therapeutics Market, 2018 - 2030 (USD Million)
    • 7.4.3. Germany
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Market Scenario
      • 7.4.3.4. Regulatory Framework
      • 7.4.3.5. Disease Prevalence
      • 7.4.3.6. Reimbursement Scenario
      • 7.4.3.7. Germany mRNA Therapeutics Market, 2018 - 2030 (USD Million)
    • 7.4.4. France
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. Market Scenario
      • 7.4.4.4. Regulatory Framework
      • 7.4.4.5. Disease Prevalence
      • 7.4.4.6. Reimbursement Scenario
      • 7.4.4.7. France mRNA Therapeutics Market, 2018 - 2030 (USD Million)
    • 7.4.5. Italy
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Competitive Scenario
      • 7.4.5.3. Market Scenario
      • 7.4.5.4. Regulatory Framework
      • 7.4.5.5. Disease Prevalence
      • 7.4.5.6. Reimbursement Scenario
      • 7.4.5.7. Italy mRNA Therapeutics Market, 2018 - 2030 (USD Million)
    • 7.4.6. Spain
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Competitive Scenario
      • 7.4.6.3. Market Scenario
      • 7.4.6.4. Regulatory Framework
      • 7.4.6.5. Disease Prevalence
      • 7.4.6.6. Reimbursement Scenario
      • 7.4.6.7. Spain mRNA Therapeutics Market, 2018 - 2030 (USD Million)
    • 7.4.7. Denmark
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Competitive Scenario
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. Disease Prevalence
      • 7.4.7.5. Reimbursement Scenario
      • 7.4.7.6. Denmark mRNA Therapeutics Market, 2018 - 2030 (USD Million)
    • 7.4.8. Sweden
      • 7.4.8.1. Key Country Dynamics
      • 7.4.8.2. Market Scenario
      • 7.4.8.3. Regulatory Framework
      • 7.4.8.4. Disease Prevalence
      • 7.4.8.5. Reimbursement Scenario
      • 7.4.8.6. Sweden mRNA Therapeutics Market, 2018 - 2030 (USD Million)
    • 7.4.9. Norway
      • 7.4.9.1. Key Country Dynamics
      • 7.4.9.2. Competitive Scenario
      • 7.4.9.3. Regulatory Framework
      • 7.4.9.4. Disease Prevalence
      • 7.4.9.5. Reimbursement Scenario
      • 7.4.9.6. Norway mRNA Therapeutics Market, 2018 - 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Asia Pacific mRNA Therapeutics Market, 2018 - 2030 (USD Million)
    • 7.5.2. Japan
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Scenario
      • 7.5.2.5. Japan mRNA Therapeutics Market, 2018 - 2030 (USD Million)
    • 7.5.3. China
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Scenario
      • 7.5.3.5. China mRNA Therapeutics Market, 2018 - 2030 (USD Million)
    • 7.5.4. India
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Scenario
      • 7.5.4.5. India mRNA Therapeutics Market, 2018 - 2030 (USD Million)
    • 7.5.5. Australia
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Reimbursement Scenario
      • 7.5.5.5. Australia mRNA Therapeutics Market, 2018 - 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Reimbursement Scenario
      • 7.5.6.5. Thailand mRNA Therapeutics Market, 2018 - 2030 (USD Million)
    • 7.5.7. South Korea
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Reimbursement Scenario
      • 7.5.7.5. South Korea mRNA Therapeutics Market, 2018 - 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Latin America mRNA Therapeutics Market, 2018 - 2030 (USD Million)
    • 7.6.2. Brazil
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Scenario
      • 7.6.2.5. Brazil mRNA Therapeutics Market, 2018 - 2030 (USD Million)
    • 7.6.3. Mexico
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Scenario
      • 7.6.3.5. Mexico mRNA Therapeutics Market, 2018 - 2030 (USD Million)
    • 7.6.4. Argentina
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Scenario
      • 7.6.4.5. Argentina mRNA Therapeutics Market, 2018 - 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. MEA mRNA Therapeutics Market, 2018 - 2030 (USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Market Scenario
      • 7.7.2.4. Regulatory Framework
      • 7.7.2.5. Disease Prevalence
      • 7.7.2.6. Reimbursement Scenario
      • 7.7.2.7. South Africa mRNA Therapeutics Market, 2018 - 2030 (USD Million)
    • 7.7.3. Saudi Arabia
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement Scenario
      • 7.7.3.5. Saudi Arabia mRNA Therapeutics Market, 2018 - 2030 (USD Million)
    • 7.7.4. UAE
      • 7.7.4.1. Key Country Dynamics
      • 7.7.4.2. Competitive Scenario
      • 7.7.4.3. Regulatory Framework
      • 7.7.4.4. Reimbursement Scenario
      • 7.7.4.5. UAE mRNA Therapeutics Market, 2018 - 2030 (USD Million)
    • 7.7.5. Kuwait
      • 7.7.5.1. Key Country Dynamics
      • 7.7.5.2. Competitive Scenario
      • 7.7.5.3. Regulatory Framework
      • 7.7.5.4. Reimbursement Scenario
      • 7.7.5.5. Kuwait mRNA Therapeutics Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Position Analysis, 2023
  • 8.4. Company Profiles/Listing
    • 8.4.1. Moderna Inc.
      • 8.4.1.1. Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Strategic Initiatives
    • 8.4.2. BioNTech SE
      • 8.4.2.1. Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Strategic Initiatives
    • 8.4.3. CureVac N.V.
      • 8.4.3.1. Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Strategic Initiatives
    • 8.4.4. Arcturus Therapeutics
      • 8.4.4.1. Overview
      • 8.4.4.2. Product Benchmarking
      • 8.4.4.3. Strategic Initiatives
    • 8.4.5. Sanofi
      • 8.4.5.1. Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Strategic Initiatives
    • 8.4.6. GSK plc.
      • 8.4.6.1. Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Strategic Initiatives
    • 8.4.7. Argos Therapeutics Inc.
      • 8.4.7.1. Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Strategic Initiatives
    • 8.4.8. Ethris
      • 8.4.8.1. Overview
      • 8.4.8.2. Product Benchmarking
      • 8.4.8.3. Strategic Initiatives
    • 8.4.9. Pfizer Inc.
      • 8.4.9.1. Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Strategic Initiatives
    • 8.4.10. AstraZeneca
      • 8.4.10.1. Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Global mRNA therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America mRNA therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 4 North America mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 5 North America mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 6 North America mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 7 U.S. mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 8 U.S. mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 9 U.S. mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 10 Canada mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 11 Canada mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 12 Canada mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 13 Europe mRNA therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 14 Europe mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 15 Europe mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 16 Europe mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 17 Germany mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 18 Germany mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 19 Germany mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 20 UK mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 21 UK mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 22 UK mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 23 France mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 24 France mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 25 France mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 26 Italy mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 27 Italy mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 28 Italy mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 29 Spain mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 30 Spain mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 31 Spain mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 32 Denmark mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 33 Denmark mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 34 Denmark mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 35 Sweden mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 36 Sweden mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 37 Sweden mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 38 Norway mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 39 Norway mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 40 Norway mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific mRNA therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 45 China mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 46 China mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 47 China mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 48 Japan mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 49 Japan mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 50 Japan mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 51 India mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 52 India mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 53 India mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 54 South Korea mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 55 South Korea mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 56 South Korea mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 57 Australia mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 58 Australia mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 59 Australia mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 60 Thailand mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 61 Thailand mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 62 Thailand mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 63 Latin America mRNA therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 64 Latin America mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 65 Latin America mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 66 Latin America mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 67 Brazil mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 68 Brazil mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 69 Brazil mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 70 Mexico mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 71 Mexico mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 72 Mexico mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 73 Argentina mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 74 Argentina mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 75 Argentina mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 76 MEA mRNA therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 77 MEA mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 78 MEA mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 79 MEA mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 80 South Africa mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 81 South Africa mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 82 South Africa mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 85 Saudi Arabia mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 86 UAE mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 87 UAE mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 88 UAE mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 89 Kuwait mRNA therapeutics market, by type, 2018 - 2030 (USD Million)
  • Table 90 Kuwait mRNA therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 91 Kuwait mRNA therapeutics market, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Market formulation & validation
  • Fig. 6 mRNA therapeutics market: market outlook
  • Fig. 7 mRNA therapeutics competitive insights
  • Fig. 8 Parent market outlook
  • Fig. 9 Related/ancillary market outlook
  • Fig. 10 mRNA therapeutics market driver impact
  • Fig. 11 mRNA therapeutics market restraint impact
  • Fig. 12 mRNA therapeutics market strategic initiatives analysis
  • Fig. 13 mRNA therapeutics market: type movement analysis
  • Fig. 14 mRNA therapeutics market: type outlook and key takeaways
  • Fig. 15 Prophylactic market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 16 Therapeutic market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 17 mRNA therapeutics market: application movement analysis
  • Fig. 18 mRNA therapeutics market: application outlook and key takeaways
  • Fig. 19 Infectious diseases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Rare genetic diseases market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 22 Respiratory diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 mRNA therapeutics market: end-use movement analysis
  • Fig. 25 mRNA therapeutics market: end-use outlook and key takeaways
  • Fig. 26 Hospitals & clinics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Research organizations market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 North America mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 U.S. mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Canada mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Europe mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 UK mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Germany mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 France mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Italy mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Spain mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Denmark mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Sweden mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Norway mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Asia Pacific mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 China mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Japan mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 India mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Thailand mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 South Korea mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Australia mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Latin America mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Brazil mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Mexico mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Argentina mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Middle East and Africa mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 South Africa mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Saudi Arabia mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 UAE mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Kuwait mRNA therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Market positioning of key market players- mRNA therapeutics market